PT2505578E - Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários - Google Patents

Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários Download PDF

Info

Publication number
PT2505578E
PT2505578E PT121626261T PT12162626T PT2505578E PT 2505578 E PT2505578 E PT 2505578E PT 121626261 T PT121626261 T PT 121626261T PT 12162626 T PT12162626 T PT 12162626T PT 2505578 E PT2505578 E PT 2505578E
Authority
PT
Portugal
Prior art keywords
intermediates
inhibitors
compounds
methods
dipeptidyl peptidase
Prior art date
Application number
PT121626261T
Other languages
English (en)
Inventor
Ronald L Hanson
Ramesh N Patel
David J Augeri
Lawrence G Hamann
Truc Chi Vu
David B Brzozowski
Sergei V Kolotuchin
Kwok Wong
Jurong Yu
Rita Fox
Jollie Duaine Godfrey
David R Magnin
John A Mazzullo
Jianji Wang
Jason Zhu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2505578(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT2505578E publication Critical patent/PT2505578E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C07C62/06—Saturated compounds containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C07C69/635—Halogen-containing esters of saturated acids containing rings in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT121626261T 2002-12-09 2003-12-04 Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários PT2505578E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43181402P 2002-12-09 2002-12-09

Publications (1)

Publication Number Publication Date
PT2505578E true PT2505578E (pt) 2014-12-17

Family

ID=32507798

Family Applications (4)

Application Number Title Priority Date Filing Date
PT121626246T PT2517706E (pt) 2002-12-09 2003-12-04 Métodos e compostos para a produção de inibidores de dipeptidil peptidase iv e seus intermediários
PT38127999T PT1581487E (pt) 2002-12-09 2003-12-04 Métodos e compostos para a produção de inibidores de dipeptidil peptidase iv e seus intermediários
PT121626337T PT2505579E (pt) 2002-12-09 2003-12-04 Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários
PT121626261T PT2505578E (pt) 2002-12-09 2003-12-04 Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PT121626246T PT2517706E (pt) 2002-12-09 2003-12-04 Métodos e compostos para a produção de inibidores de dipeptidil peptidase iv e seus intermediários
PT38127999T PT1581487E (pt) 2002-12-09 2003-12-04 Métodos e compostos para a produção de inibidores de dipeptidil peptidase iv e seus intermediários
PT121626337T PT2505579E (pt) 2002-12-09 2003-12-04 Métodos e compostos para produzir inibidores de dipeptidil peptidase iv e seus intermediários

Country Status (17)

Country Link
US (4) US7420079B2 (pt)
EP (5) EP2517706B1 (pt)
JP (6) JP4886193B2 (pt)
KR (1) KR20050088309A (pt)
CN (3) CN102942482B (pt)
AU (1) AU2003297647A1 (pt)
BR (1) BR0317139A (pt)
CA (1) CA2508619A1 (pt)
DK (4) DK2505578T3 (pt)
ES (4) ES2484915T3 (pt)
IL (1) IL192912A0 (pt)
MX (1) MXPA05005970A (pt)
PL (1) PL377123A1 (pt)
PT (4) PT2517706E (pt)
SI (4) SI2517706T1 (pt)
TW (2) TW200914419A (pt)
WO (1) WO2004052850A2 (pt)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0487425A (ja) * 1990-07-31 1992-03-19 Fujitsu Ltd 回線切り替え装置
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR20150028829A (ko) 2003-11-17 2015-03-16 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
ES2940341T3 (es) 2004-01-20 2023-05-05 Novartis Ag Formulación y proceso de compresión directa
TW200538122A (en) * 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) * 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) * 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) * 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
DE102004035978A1 (de) * 2004-07-23 2006-03-16 Justus-Liebig-Universität Giessen Aminoadamantan-Verbindungen
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7250529B2 (en) 2004-09-17 2007-07-31 Albemarle Corporation Synthesis process for 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006107963A2 (en) * 2005-04-06 2006-10-12 Novartis Ag Process for preparing dipeptide amides
US7205432B2 (en) * 2005-05-31 2007-04-17 Kemfine Oy Process for the preparation of adamantane derivatives
FI120765B (fi) * 2005-05-31 2010-02-26 Kemfine Group Ltd Menetelmä adamantaanijohdannaisten valmistamiseksi
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DK1942898T4 (da) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP2009533393A (ja) 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
CN101415676A (zh) 2006-04-17 2009-04-22 住友化学株式会社 N-叔丁氧基羰基-2-吡咯烷酮类及其制造方法
JP5272324B2 (ja) * 2006-04-17 2013-08-28 住友化学株式会社 Ｎ−ｔｅｒｔ−ブトキシカルボニル−２−ピロリジノン類およびその製造方法
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
KR101171480B1 (ko) 2007-07-02 2012-08-07 에프. 호프만-라 로슈 아게 Ｃｃｒ-2 수용체 길항제로서의 이미다졸 유도체
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
WO2009037719A1 (en) * 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US20100124541A1 (en) * 2008-11-19 2010-05-20 Auspex Pharmaceuticals, Inc. Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US20100256153A1 (en) * 2009-03-27 2010-10-07 Bristol-Myers Squibb Company Methods for preventing or reducing risk of mortality
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101292379B1 (ko) * 2009-04-08 2013-08-09 브리스톨-마이어스 스큅 컴퍼니 Ｐｄｈ 및 ｆｄｈ 효소를 발현하는 유전적으로 안정한 플라스미드
ES2548386T3 (es) * 2009-04-09 2015-10-16 Sandoz Ag Formas cristalinas de saxagliptina
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
FR2956400A1 (fr) 2010-02-15 2011-08-19 Finorga Procede de preparation de composes adamantyles
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2368874A1 (en) 2010-03-26 2011-09-28 Sandoz AG Racemisation of (R)-N-Boc-3-hydroxyadamant-1-yl glycine
AU2011237775A1 (en) 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8501960B2 (en) 2010-05-05 2013-08-06 Assia Chemical Industries Ltd. Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
EP2611770A1 (en) 2010-09-03 2013-07-10 Sandoz AG Process for the reductive amination of -keto carboxylic acids
KR20130137624A (ko) 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
CA2812699A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8410288B2 (en) 2010-10-04 2013-04-02 Teva Pharmaceutical Industries Ltd. Polymorphs of Saxagliptin hydrochloride and processes for preparing them
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8748631B2 (en) 2011-05-24 2014-06-10 Apicore, Llc Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JPWO2013081100A1 (ja) * 2011-11-30 2015-04-27 積水メディカル株式会社 アダマンチルヒダントイン化合物
ITMI20120842A1 (it) * 2012-05-16 2013-11-17 Chemelectiva S R L Intermedi utili per la preparazione di saxagliptina e processo per la loro preparazione
WO2013175395A2 (en) * 2012-05-21 2013-11-28 Dr. Reddys Laboratories Limited Improved process for preparation of saxagliptin and its salts
US8664443B2 (en) 2012-05-23 2014-03-04 Divi's Laboratories Ltd. Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2861560B1 (en) 2012-05-24 2018-08-08 Apotex Inc. Salts of saxagliptin with organic acids
AU2013285078A1 (en) 2012-07-02 2015-01-29 Sun Pharmaceutical Industries Limited Saxagliptin salts
CN103539724B (zh) * 2012-07-12 2017-09-26 博瑞生物医药（苏州）股份有限公司 沙格列汀单一立体异构体的新晶型和纯化方法
WO2014057495A1 (en) 2012-10-11 2014-04-17 Lee Pharma Limited A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014108830A1 (en) 2013-01-10 2014-07-17 Wockhardt Limited A process for preparing pharmaceutically acceptable salt of saxagliptin
CN104098481B (zh) * 2013-04-10 2016-05-11 浙江九洲药物科技有限公司 一种沙格列汀中间体的制备方法
CN103265473A (zh) * 2013-06-04 2013-08-28 上海同昌生物医药科技有限公司 一种生产沙格列汀的方法
CN104370769B (zh) * 2013-08-14 2017-05-31 重庆博腾制药科技股份有限公司 一种制备羟基金刚烷甘氨酸衍生物的方法
US9416105B2 (en) 2013-08-28 2016-08-16 Amneal Pharmaceuticals Llc Process for preparation of saxagliptin and its hydrochloride salt
CN103450071A (zh) * 2013-09-05 2013-12-18 南京工业大学 一种医药中间体2-氮杂双环[3.1.0]己烷-2,3-二碳酸叔丁酯的不对称合成方法
CN103467360A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构r-脯氨酸的吗啉衍生物及其制备方法
CN103467361A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构s-脯氨酸的吗啉衍生物及其制备方法
CN103467362A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构s-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103435536A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构s-脯氨酸的吡咯衍生物及其制备方法
CN103435535A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构r-脯氨酸的制备方法
CN103450073A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构r-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103435533A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构的s-脯氨醇手性有机小分子化合物及其合成方法
CN103450074A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构的r-脯氨醇手性有机小分子化合物及其合成方法
CN103435534A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构s-脯氨酸的制备方法
CN104649953A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种沙格列汀倍半水合物化合物
WO2015087262A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Process for the preparation of saxagliptin and its intermediates
CN104829444A (zh) * 2014-02-12 2015-08-12 上海医药工业研究院 一种α-溴代三环[3.3.1.13,7]癸烷-1-乙酸的后处理方法
CN103910669B (zh) * 2014-04-04 2015-10-21 苏州景泓生物技术有限公司 沙格列汀关键中间体的制备方法
CN103951588B (zh) * 2014-04-30 2016-10-05 淮海工学院 一种合成沙格列汀中间体n-叔丁氧羰基-3-羟基-1-金刚烷基-d-甘氨酸的方法
CN104109100A (zh) * 2014-05-29 2014-10-22 上海应用技术学院 一种金刚烷氨基酸酯化合物的合成方法
CN105315189A (zh) * 2014-05-29 2016-02-10 上海医药工业研究院 一种制备（5s）-5-氨基羰基-4,5-二氢-1h-吡咯-1-羧酸-1（1,1-二甲基乙基）酯的方法
CN104098487A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种n-叔丁氧羰基-3-羟基-1-金刚烷基甘氨酸的制备方法
CN104098505A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种沙格列汀的制备方法
WO2016026827A1 (en) * 2014-08-20 2016-02-25 Sandoz Ag Crystalline boc-s-hadgly and process for its preparation
CN104293844B (zh) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 一种特拉匹韦中间体的合成方法
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CN105503698A (zh) * 2014-09-26 2016-04-20 深圳翰宇药业股份有限公司 一种合成沙格列汀及其中间体的方法
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN104817476B (zh) * 2015-03-25 2020-09-11 重庆医科大学 一种制备非天然氨基酸的方法
CN105037245B (zh) * 2015-08-03 2017-04-12 沧州那瑞化学科技有限公司 一种沙格列汀中间体的制备方法
CN105112469B (zh) * 2015-09-24 2018-07-27 福建省微生物研究所 酶催化不对称转氨基反应制备沙格列汀手性中间体的方法
CN106554301B (zh) * 2015-09-30 2018-09-21 深圳翰宇药业股份有限公司 一种沙格列汀关键中间体的制备方法
KR101715682B1 (ko) 2015-10-29 2017-03-13 경동제약 주식회사 삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법
DE102016116130A1 (de) 2016-08-30 2018-03-01 Universität Bielefeld Verfahren zur Herstellung chiraler Aminonitrile
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN112567468A (zh) 2018-06-14 2021-03-26 阿斯利康(英国)有限公司 用二肽基肽酶-4抑制剂药物组合物降低血糖的方法
EP3914605B1 (en) * 2019-01-24 2022-12-07 DSM IP Assets B.V. Peptide precipitation method
CN111170927B (zh) * 2020-04-10 2020-08-04 上海翰森生物医药科技有限公司 一种沙格列汀中间体的制备方法
CN114621068A (zh) * 2022-03-31 2022-06-14 沧州那瑞化学科技有限公司 3-羟基-1-金刚烷甲基酮的制备方法及合成沙格列汀的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325478A (en) * 1964-11-17 1967-06-13 Du Pont alpha-amino-1-adamantylmethyl penicillins
US3646066A (en) * 1970-03-25 1972-02-29 Squibb & Sons Inc Adamantylamino-tetrahydronaphthyl-oxypropanols and ester derivatives
SU910605A1 (ru) * 1980-06-23 1982-03-07 Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции Способ получени @ -амино-1-адамантилуксусной кислоты
EP0140503A1 (en) 1983-08-16 1985-05-08 Genentech, Inc. An efficient process for preparing L-amino acids in bacteria
JPS62200861A (ja) 1986-02-28 1987-09-04 Toshiba Corp 画像形成装置
JPH06102027B2 (ja) * 1987-08-13 1994-12-14 財団法人相模中央化学研究所 Ｌ−２−アミノ−４−フェニル酪酸の製造方法
CA2008702A1 (en) * 1989-02-27 1990-08-27 Ronald L. Hanson Process for transformation of hydroxyketo acids to hydroxyamino acids
IL120873A0 (en) 1996-05-24 1997-09-30 Tanabe Seiyaku Co Process for preparing optically active 2-halogen-3-hydroxypropionic acid ester
US6093330A (en) 1997-06-02 2000-07-25 Cornell Research Foundation, Inc. Microfabrication process for enclosed microstructures
US6068991A (en) * 1997-12-16 2000-05-30 Bristol-Myers Squibb Company High expression Escherichia coli expression vector
EP1097236A4 (en) 1998-07-15 2006-10-04 Bristol Myers Squibb Co STEREOSELECTIVE REDUCING AMINATION OF KETONES
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP3942846B2 (ja) * 2001-06-21 2007-07-11 独立行政法人科学技術振興機構 組織特異的トランスポーター阻害剤
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR20150028829A (ko) 2003-11-17 2015-03-16 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor

Also Published As

Publication number Publication date
DK2517706T3 (da) 2014-09-08
EP2792672A3 (en) 2014-11-26
DK1581487T3 (da) 2014-07-28
EP2517706A2 (en) 2012-10-31
WO2004052850A2 (en) 2004-06-24
JP2014012689A (ja) 2014-01-23
BR0317139A (pt) 2005-11-29
ES2525593T3 (es) 2014-12-26
JP2006516121A (ja) 2006-06-22
JP2016040282A (ja) 2016-03-24
JP4886193B2 (ja) 2012-02-29
US8278462B2 (en) 2012-10-02
PT2505579E (pt) 2015-01-02
EP2505578A2 (en) 2012-10-03
EP2505579B1 (en) 2014-11-05
EP2505579A2 (en) 2012-10-03
CN102070451B (zh) 2015-07-15
CN102942482B (zh) 2015-11-18
EP2517706B1 (en) 2014-06-25
JP2011006440A (ja) 2011-01-13
US20050090539A1 (en) 2005-04-28
EP1581487B1 (en) 2014-06-04
EP2505578B1 (en) 2014-09-24
SI2517706T1 (sl) 2014-09-30
JP2011006441A (ja) 2011-01-13
JP2013153748A (ja) 2013-08-15
ES2484915T3 (es) 2014-08-12
EP2505579A3 (en) 2013-08-07
EP2792672A2 (en) 2014-10-22
CN102942482A (zh) 2013-02-27
CN1791401B (zh) 2012-10-03
US7420079B2 (en) 2008-09-02
JP5511582B2 (ja) 2014-06-04
WO2004052850A3 (en) 2006-03-02
TW200914419A (en) 2009-04-01
DK2505579T3 (en) 2015-01-19
CN102070451A (zh) 2011-05-25
JP5345986B2 (ja) 2013-11-20
DK2505578T3 (en) 2014-12-08
ES2494793T3 (es) 2014-09-16
US20130012723A1 (en) 2013-01-10
EP1581487A2 (en) 2005-10-05
US7705033B2 (en) 2010-04-27
IL192912A0 (en) 2009-02-11
MXPA05005970A (es) 2005-08-18
PT2517706E (pt) 2014-09-05
AU2003297647A1 (en) 2004-06-30
SI2505578T1 (sl) 2014-12-31
US20100274025A1 (en) 2010-10-28
KR20050088309A (ko) 2005-09-05
PT1581487E (pt) 2014-09-08
EP2517706A3 (en) 2013-03-20
PL377123A1 (pl) 2006-01-23
TW200512191A (en) 2005-04-01
JP5860007B2 (ja) 2016-02-16
SI1581487T1 (sl) 2014-09-30
ES2526138T3 (es) 2015-01-07
US20090018311A1 (en) 2009-01-15
EP2505578A3 (en) 2013-07-31
CN1791401A (zh) 2006-06-21
SI2505579T1 (sl) 2015-01-30
EP1581487A4 (en) 2007-08-08
JP5730341B2 (ja) 2015-06-10
CA2508619A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
SI1581487T1 (sl) Postopek in spojine za proizvodnjo dipeptidil peptidaze iv inhibitorjev in njihovih intermediatov
IL178520A0 (en) Process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor
AU2003286776A1 (en) Novel inhibitors of dipeptidyl peptidase iv
EP1465891A4 (en) INHIBITORS OF DIPEPTIDYLPEPTIDASE IV
PL370220A1 (en) Inhibitors of dipeptidyl peptidase iv
AU2003207881A1 (en) Dipeptidyl peptidase inhibitors
IL174608A0 (en) Pyridine compounds as inhibitors of dipeptidyl peptidase iv
HUS1400007I1 (hu) Dipeptidil-peptidáz inhibitorok
AU2003232405A1 (en) Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
IL151588A0 (en) Inhibitors of dipeptidyl peptidase iv
EG25854A (en) Cyclopropyl fused pyrrolidine based inhibitors of dipeptidyl peptidase iv method
AU2003270785A1 (en) Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
IL161158A0 (en) N - substituted pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
IL187304A0 (en) Pyrrolopyridine - based inhibitors of dipeptidyl peptidase iv and methods
ZA200603153B (en) Pyridine compounds as inhibitors of dipetidyl peptidase IV
AU2003256323A8 (en) Sos1 inhibitors
AU2003248710A1 (en) Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents
AU2003253369A1 (en) Three-dimensional structure of dipeptidyl peptidase iv
ZA200709629B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
GB2394492B (en) Method for enhancing well productivity
AU2002315472A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors